Digestive Diseases and Sciences

, Volume 47, Issue 8, pp 1665–1678

REVIEW: What the Gastroenterologist Should Know About the Gastrointestinal Safety Profiles of Bisphosphonates

  • David Y. Graham


Bisphosphonates are widely prescribed to treat Paget's disease of the bone and to prevent and treat osteoporosis. Soon after the release of alendronate, esophagitis and esophageal strictures were encountered, resulting in labeling changes. Subsequent endoscopic studies in normal subjects showed that alendronate also caused gastric erosions and ulcers. Although the clinical significance of these is still uncertain, the anatomic distribution of both the gastric ulcers and esophageal damage is consistent with a topical irritant effect. Recent data also suggest a synergistic ulcerogenic potential of concurrent alendronate and NSAID use. A 70-mg once-weekly dosage form of alendronate has recently been approved and clinical experience with its gastrointestinal tolerability is ongoing. Risedronate, a third-generation bisphosphonate, appears to have less ulcerogenic potential than alendronate, and esophageal stricture has not been reported. Experience with the bisphosphonates provide a paradigm for the critical role of endoscopists in evaluating the gastrointestinal profile of new drugs. As bisphosphonates are more widely prescribed and more types of bisphosphonates are developed, the role of the gastroenterologist is likely to assume even more importance.

bisphosphonates risedronate alendronate tolerability endoscopy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Russell RG, Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Croucher PI, Shipman C, Fleisch HA: The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res 14(suppl 2):53–65, 1999PubMedGoogle Scholar
  2. 2.
    Gatti D, Adami S: New bisphosphonates in the treatment of bone diseases. Drugs Aging 15:285–296, 1999PubMedGoogle Scholar
  3. 3.
    Watts NB: Treatment of osteoporosis with bisphosphonates. Rheum Dis Clin North Am 27:197–214, 2001PubMedGoogle Scholar
  4. 4.
    Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I: Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet 340:1049–1052, 1992PubMedGoogle Scholar
  5. 5.
    Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S: Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11:59–65, 1993PubMedGoogle Scholar
  6. 6.
    Kanis JA, Powles T, Paterson AH, McCloskey EV, Ashley S: Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 19:663–667, 1996PubMedGoogle Scholar
  7. 7.
    McCloskey EV, MacLennan IC, Drayson MT, Chapman C, Dunn J, Kanis JA: A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol 100:317–325, 1998PubMedGoogle Scholar
  8. 8.
    McCloskey E, Selby P, de Takats D, Bernard J, Davies M, Robinson J, Francis R, Adams J, Pande K, Beneton M, Jalava T, Loyttyniemi E, Kanis JA: Effects of clodronate on vertebral fracture risk in osteoporosis: A 1-year interim analysis. Bone 28:310–315, 2001PubMedGoogle Scholar
  9. 9.
    Powles TJ, McCloskey E, Paterson AH, Ashley S, Tidy VA, Nevantaus A, Rosenqvist K, Kanis J: Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 90:704–708, 1998PubMedGoogle Scholar
  10. 10.
    Eyres KS, Marshall P, McCloskey E, Douglas DL, Kanis JA: Spontaneous fractures in a patient treated with low doses of etidronic acid (disodium etidronate). Drug Saf 7:162–165, 1992PubMedGoogle Scholar
  11. 11.
    Storm T, Steiniche T, Thamsborg G, Melsen F: Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. J Bone Miner Res 8:199–208, 1993PubMedGoogle Scholar
  12. 12.
    Miller PD, Watts NB, Licata AA, Harris ST, Genant HK, Wasnich RD, Ross PD, Jackson RD, Hoseyni MS, Schoenfeld SL, Valent DJ, Chesnut CH 3rd: Cyclical etidronate in the treatment of postmenopausal osteoporosis: Efficacy and safety after seven years of treatment. Am J Med 103:468–476, 1997PubMedGoogle Scholar
  13. 13.
    Greenspan SL, Harris ST, Bone H, Miller PD, Orwoll ES, Watts NB, Rosen CJ: Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis. Am Fam Physician 61:2731–2736, 2000PubMedGoogle Scholar
  14. 14.
    Miller PD, Brown JP, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ: A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group. Am J Med 106:513–520, 1999PubMedGoogle Scholar
  15. 15.
    Sahota, Fowler I, Blackwell PJ, Lawson N, Cawte SA, San P, Masud T, Hosking DJ: A comparison of continuous alendronate, cyclical alendronate and cyclical etidronate with calcitriol in the treatment of postmenopausal vertebral osteoporosis: A randomized controlled trial. Osteoporos Int 11:959–966, 2000PubMedGoogle Scholar
  16. 16.
    Fairney A, Kyd P, Thomas E, Wilson J: Response to alendronate in osteoporosis after previous treatment with etidronate. Osteoporos Int 11:621–625, 2000PubMedGoogle Scholar
  17. 17.
    van Staa T, Abenhaim L, Cooper C: Upper gastrointestinal adverse events and cyclical etidronate. Am J Med 103:462–467, 1997PubMedGoogle Scholar
  18. 18.
    Kellihan MJ, Mangino PD: Pamidronate. Ann Pharmacother 26:1262–1269, 1992PubMedGoogle Scholar
  19. 19.
    Papapoulos SE: Bisphosphonates: Pharmacology and use in the treatment of osteoporosis. In Osteoporosis. R Marcus, D Feldman, J Kelsey (eds). San Diego, Academic Press, 1996, pp 1209–1234Google Scholar
  20. 20.
    Ryan PJ, Blake GM, Davie M, Haddaway M, Gibson T, Fogelman I: Intermittent oral disodium pamidronate in established osteoporosis: A 2 year double-masked placebocontrolled study of efficacy and safety. Osteoporos Int 11:171–176, 2000PubMedGoogle Scholar
  21. 21.
    Reid IR, King AR, Alexander CJ, Ibbertson HK: Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1:143–146, 1988PubMedGoogle Scholar
  22. 22.
    Dodwell DJ, Howell A, Ford J: Reduction in calcium excretion in women with breast cancer and bone metastases using the oral bisphosphonate pamidronate. Br J Cancer 61:123–125, 1990PubMedGoogle Scholar
  23. 23.
    Lufkin EG, Argueta R, Whitaker MD, Cameron AL, Wong VH, Egan KS, O'Fallon WM, Riggs BL: Pamidronate: An unrecognized problem in gastrointestinal tolerability. Osteoporos Int 4:320–322, 1994PubMedGoogle Scholar
  24. 24.
    Aredia Product Monograph. Novartis 1999.Google Scholar
  25. 25.
    Reid IR, Nicholson GC, Weinstein RS, Hosking DJ, Cundy T, Kotowicz MA, Murphy WA Jr, Yeap S, Dufresne S, Lombardi A, Musliner TA, Thompson DE, Yates AJ: Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial. Am J Med 101:341–348, 1996PubMedGoogle Scholar
  26. 26.
    Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG: Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339:292–299, 1998PubMedGoogle Scholar
  27. 27.
    Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, Doherty SM, Maricic M, Rosen C, Brown J, Barton I, Chines AA: Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67:277–285, 2000PubMedGoogle Scholar
  28. 28.
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541, 1996CrossRefPubMedGoogle Scholar
  29. 29.
    Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Jr, Dequeker J, Favus M: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437–1443, 1995CrossRefPubMedGoogle Scholar
  30. 30.
    McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY: Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340, 2001PubMedGoogle Scholar
  31. 31.
    Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH, 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352, 1999PubMedGoogle Scholar
  32. 32.
    Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R: Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83–91, 2000PubMedGoogle Scholar
  33. 33.
    Nightingale SL: From the Food and Drug Administration. JAMA 275:1534, 1996PubMedGoogle Scholar
  34. 34.
    Siris E: Alendronate in the treatment of osteoporosis: a review of the clinical trials. J Womens Health Gend Based Med 9:599–606, 2000PubMedGoogle Scholar
  35. 35.
    Crandall C: Risedronate: A clinical review. Arch Intern Med 161:353–360, 2001PubMedGoogle Scholar
  36. 36.
    Watts NB, Freedholm D, Daifotis A: The clinical tolerability profile of alendronate. Int J Clin Prac Suppl 101:51–61, 1999Google Scholar
  37. 37.
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280:2077–2082, 1998PubMedGoogle Scholar
  38. 38.
    Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P, McClung M, Balske A, Thompson D, Daley M, Yates AJ: Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med 338:485–492, 1998PubMedGoogle Scholar
  39. 39.
    Liberman UI, Hirsch LJ: Esophagitis and alendronate. N Engl J Med 335:1069–1070, 1996PubMedGoogle Scholar
  40. 40.
    McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS, Fuleihan Ge-H, Reda C, Yates AJ, Ravn P: Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med 128:253–261, 1998PubMedGoogle Scholar
  41. 41.
    Ravn P, Weiss SR, Rodriguez-Portales JA, McClung MR, Wasnich RD, Gilchrist NL, Sambrook P, Fogelman I, Krupa D, Yates AJ, Daifotis A, Fuleihan GE: Alendronate in early postmenopausal women: Effects on bone mass during longterm treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. J Clin Endocrinol Metab 85:1492–1497, 2000PubMedGoogle Scholar
  42. 42.
    Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora AC, 2nd: Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 101:488–501, 1996PubMedGoogle Scholar
  43. 43.
    Bauer DC, Black D, Ensrud K, Thompson D, Hochberg M, Nevitt M, Musliner T, Freedholm D: Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 160:517–525, 2000PubMedGoogle Scholar
  44. 44.
    de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK: Esophagitis associated with the use of alendronate. N Engl J Med 335:1016–1021, 1996PubMedGoogle Scholar
  45. 45.
    Abdelmalek MF, Douglas DD: Alendronate-induced ulcerative esophagitis. Am J Gastroenterol 91:1282–1283, 1996Google Scholar
  46. 46.
    Maconi G, Porro GB: Multiple ulcerative esophagitis caused by alendronate. Am J Gastroenterol 90:1889–1890, 1995PubMedGoogle Scholar
  47. 47.
    Naylor G, Davies MH: Oesophageal stricture associated with alendronic acid. Lancet 348:1030–1031, 1996Google Scholar
  48. 48.
    Sorrentino D, Trevisi A, Bernardis V, DeBiase F, Labombarda A, Bartoli E: Esophageal ulceration due to alendronate. Endoscopy 28:529, 1996PubMedGoogle Scholar
  49. 49.
    Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora 2nd AC, Saur A, Thompson DE, Yates J, Orloff JJ: Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 12:1–12, 2000Google Scholar
  50. 50.
    Daoud M, Licata AA: Side effect profile of alendronate in clinical practice. J Bone Min Res 12(suppl 1):S469, 1997 (abstract)Google Scholar
  51. 51.
    Kelly R, Taggart H: Incidence of gastrointestinal side effects due to alendronate is high in clinical practice. BMJ 315:1235, 1997Google Scholar
  52. 52.
    Ettinger B, Pressman A, Schein J: Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manage Care 4:1377–1382, 1998Google Scholar
  53. 53.
    Ettinger B, Pressman A, Schein J, et al: Alendronate use among 812 women: Prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J Manage Care Pharm 4:488–492, 1998Google Scholar
  54. 54.
    Colina RE, Smith M, Kikendall JW, Wong RK: A new probable increasing cause of esophageal ulceration: Alendronate. Am J Gastroenterol 92:704–706, 1997PubMedGoogle Scholar
  55. 55.
    Cameron RB: Esophagitis dissecans superficialis and alendronate: Case report. Gastrointest Endosc 46:562–563, 1997PubMedGoogle Scholar
  56. 56.
    Levine J, Nelson D: Esophageal stricture associated with alendronate therapy. Am J Med 102:489–491, 1997PubMedGoogle Scholar
  57. 57.
    Ryan JM, Kelsey P, Ryan BM, Mueller PR: Alendronateinduced esophagitis: Case report of a recently recognized form of severe esophagitis with esophageal stricture— radiographic features. Radiology 206:389–391, 1998PubMedGoogle Scholar
  58. 58.
    Ribeiro A, DeVault KR, Wolfe JT 3rd, Stark ME: Alendronate-associated esophagitis: Endoscopic and pathologic features. Gastrointest Endosc 47:525–528, 1998PubMedGoogle Scholar
  59. 59.
    Abraham SC, Cruz-Correa M, Lee LA, Yardley JH, Wu TT: Alendronate-associated esophageal injury: Pathologic and endoscopic features. Mod Pathol 12:1152–1157, 1999PubMedGoogle Scholar
  60. 60.
    Lanza FL, Hunt RH, Thomson AB, Provenza JM, Blank MA: Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 119:631–638, 2000PubMedGoogle Scholar
  61. 61.
    Thomson ABR, Marshall JK, Hunt RH, et al: Incidence of gastric ulcers lower in postmenopausal women treated with risedronate than alendronate, regardless of H. Pylori status. Gastrointest Endosc 53:AB202, 2001 (abstract).Google Scholar
  62. 62.
    Graham DY, Smith JL, Bouvet AA: What happens to tablets and capsules in the stomach: Endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations. J Pharm Sci 79:420–424, 1990PubMedGoogle Scholar
  63. 63.
    Graham DY, Smith JL, Jones RD, Rakhit A, Tipnis V, Hurley ME: Gastroscopic localization of a microencapsulated KCl preparation in the human stomach. Gastrointest Endosc 33:220–223, 1987PubMedGoogle Scholar
  64. 64.
    Hey H, Matzen P, Andersen JT, Didriksen E, Nielsen B: A gastroscopic and pharmacological study of the disintegration time and absorption of pivampicillin capsules and tablets. Br J Clin Pharmacol 8:237–242, 1979PubMedGoogle Scholar
  65. 65.
    Hey H, Frederiksen HJ, Andersen JT: Gastroscopic and pharmacokinetic evaluation of a new pivmecillinam tablet. Eur J Clin Pharmacol 22:63–69, 1982PubMedGoogle Scholar
  66. 66.
    Levine MAH, Grootendorst P: Proportion of osteoporotic post-menopausal women at increased risk for upper GI adverse events associated with bisphosphonate therapy. Pharmacoepidemiol Drug Safety 9:367–370, 2000Google Scholar
  67. 67.
    Blank MA, Ems BL, Gibson GW, Myers WR, Berman SK, Phipps RJ, Smith PN: Nonclinical model for assessing gastric effects of bisphosphonates. Dig Dis Sci 42:281–288, 1997PubMedGoogle Scholar
  68. 68.
    Elliott SN, McKnight W, Davies NM, MacNaughton WK, Wallace JL: Alendronate induces gastric injury and delays ulcer healing in rodents. Life Sci 62:77–91, 1998PubMedGoogle Scholar
  69. 69.
    Graham DY, Malaty HM: Alendronate and naproxen are synergistic for development of gastric ulcers. Arch Intern Med 161:107–110, 2001PubMedGoogle Scholar
  70. 70.
    Rothschild BM, Helbling ME: Alendronate (Fosamax) interactions with nonsteroidal anti-inflammatory agents: A dangerous combination? (abstract) Arthritis Rheum 43:Suppl 9:S199, 2000Google Scholar
  71. 71.
    Mortensen L, Charles P, Bekker PJ, Digennaro J, Johnston CC Jr: Risedronate increases bone mass in an early postmenopausal population: Two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 83:396–402, 1998PubMedGoogle Scholar
  72. 72.
    Siris ES, Chines AA, Altman RD, Brown JP, Johnston CC, Jr, Lang R, McClung MR, Mallette LE, Miller PD, Ryan WG, Singer FR, Tucci JR, Eusebio RA, Bekker PJ: Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. J Bone Miner Res 13:1032–1038, 1998PubMedGoogle Scholar
  73. 73.
    Hosking D, Bockman R, Glowinski J, Moreland L, Ernst T, Geusens P, Smith C: Similar gastrointestinal side effects and endoscopic findings between risedronate and placebo-treated patients. J Bone Miner Res 15(suppl 1):S428, 2000 (abstract)Google Scholar
  74. 74.
    Lanza F, Schwartz H, Sahba B, Malaty HM, Musliner T, Reyes R, Quan H, Graham DY: An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Am J Gastroenterol 95:3112–3117, 2000PubMedGoogle Scholar
  75. 75.
    Russell RG, Croucher PI, Rogers MJ: Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 9(suppl 2):S66–S80, 1999PubMedGoogle Scholar
  76. 76.
    Lichtenberger LM, Romero JJ, Gibson GW, Blank MA: Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa. Dig Dis Sci 45:1792–1801, 2000PubMedGoogle Scholar
  77. 77.
    Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ: Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13:581–589, 1998PubMedGoogle Scholar
  78. 78.
    Reszka AA, Halasy-Nagy J, Rodan GA: Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol 59:193–202, 2001PubMedGoogle Scholar
  79. 79.
    Konttinen YT, Salo T, Hanemaaijer R, Valleala H, Sorsa T, Sutinen M, Ceponis A, Xu JW, Santavirta S, Teronen O, Lopez-Otin C: Collagenase-3 (MMP-13) and its activators in rheumatoid arthritis: localization in the pannus-hard tissue junction and inhibition by alendronate. Matrix Biol 18:401–412, 1999PubMedGoogle Scholar
  80. 80.
    Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M: Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96:384–392, 2000PubMedGoogle Scholar
  81. 81.
    Kikendall JW: Pill esophagitis. J Clin Gastroenterol 28:298–305, 1999PubMedGoogle Scholar
  82. 82.
    Graham DY, Malaty HM, Goodgame R: Primary aminobisphosphonates: A new class of gastrotoxic drugs— comparison of alendronate and aspirin. Am J Gastroenterol 92:1322–1325, 1997PubMedGoogle Scholar
  83. 83.
    Smith SJ, Lee AJ, Maddix DS, Chow AW: Pill-induced esophagitis caused by oral rifampin. Ann Pharmacother 33:27–31, 1999PubMedGoogle Scholar
  84. 84.
    Perkins AC, Wilson CG, Blackshaw PE, Vincent RM, Dansereau RJ, Juhlin KD, Bekker PJ, Spiller RC: Impaired oesophageal transit of capsule versus tablet formulations in the elderly. Gut 35:1363–1367, 1994PubMedGoogle Scholar
  85. 85.
    Channer KS, Virjee JP: The effect of formulation on oesophageal transit. J Pharm Pharmacol 37:126–129, 1985PubMedGoogle Scholar
  86. 86.
    Perkins AC, Wilson CG, Frier M, Blackshaw PE, Dansereau RJ, Vincent RM, Wenderoth D, Hathaway S, Li Z, Spiller RC: The use of scintigraphy to demonstrate the rapid esophageal transit of the oval film-coated placebo risedronate tablet compared to a round uncoated placebo tablet when administered with minimal volumes of water. Int J Pharm 222:295–303, 2001PubMedGoogle Scholar
  87. 87.
    Peter CP, Handt LK, Smith SM: Esophageal irritation due to alendronate sodium tablets: Possible mechanisms. Dig Dis Sci 43:1998–2002, 1998PubMedGoogle Scholar
  88. 88.
    Galmiche JP, Janssens J: The pathophysiology of gastrooesophageal reflux disease: an overview. Scand J Gastroenterol Suppl 211:7–18, 1995Google Scholar
  89. 89.
    Blank MA, Gibson GW, Myers WR, Dierckman TA, Phipps RJ, Smith PN: Gastric damage in the rat with nitrogencontaining bisphosphonates depends on pH. Aliment Pharmacol Ther 14:1215–1223, 2000PubMedGoogle Scholar
  90. 90.
    Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H, Lasseter KC, Mucklow JC, Porras AG: Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 58:288–298, 1995PubMedGoogle Scholar
  91. 91.
    Peter CP, Kindt MV, Majka JA: Comparative study of potential for bisphosphonates to damage gastric mucosa of rats. Dig Dis Sci 43:1009–1015, 1998PubMedGoogle Scholar
  92. 92.
    Graham DY, Malaty HM: Alendronate gastric ulcers. Aliment Pharmacol Ther 13:515–519, 1999PubMedGoogle Scholar
  93. 93.
    Kottler RE, Tuft RJ: Benign greater curve gastric ulcer: The “sump-ulcer.” Br J Radiol 54:651–654, 1981PubMedGoogle Scholar
  94. 94.
    Miller PD, Woodson G, Licata AA, Ettinger MP, Mako B, Smith ME, Wang L, Yates SJ, Melton ME, Palmisano JJ: Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. Clin Ther 22:1433–1442, 2000PubMedGoogle Scholar
  95. 95.
    Adachi JD, Adami S, Miller PD, Olszynski WP, Kendler DL, Silverman SL, Licata AA, Li Z, Gomez-Panzani E: Tolerability of risedronate in postmenopausal women intolerant of alendronate. Aging Clin Exp Res 13:347–354, 2001Google Scholar
  96. 96.
    Black DM, Reiss TF, Nevitt MC, Cauley J, Karpf D, Cummings SR: Design of the Fracture Intervention Trial. Osteoporos Int 3:S29–S39, 1993Google Scholar
  97. 97.
    Dowd R, Recker RR, Heaney RP: Study subjects and ordinary patients. Osteoporos Int 11:533–536, 2000PubMedGoogle Scholar
  98. 98.
    Hosking D, Keller M, Stevens K, Strauss D, Adachi J: Risedronate is well-tolerated in postmenopausal osteoporotic women using NSAIDs or with underlying gastrointestinal disorder. Calcif Tissue Int 66(suppl 1):2000 (abstract)Google Scholar
  99. 99.
    Lanza F, Rack MF, Simon TJ, Lombardi A, Reyes R, Suryawanshi S: Effects of alendronate on gastric and duodenal mucosa. Am J Gastroenterol 93:753–757, 1998PubMedGoogle Scholar
  100. 100.
    Herrera JA, Sarabia MO, Gonzalez MM: Effects of treatment with bisphosphonates on gastrointestinal and esophageal mucosa in patients with osteoporosis: Pamidronate versus alendronate. Curr Ther Res 60:307–313, 1999Google Scholar
  101. 101.
    Lowe CE, Depew WT, Vanner SJ, Paterson WG, Meddings JB: Upper gastrointestinal toxicity of alendronate. Am J Gastroenterol 95:634–640, 2000PubMedGoogle Scholar
  102. 102.
    Marshall JK, Rainsford KD, James C, Hunt RH: A randomized controlled trial to assess alendronate-associated injury of the upper gastrointestinal tract. Aliment Pharmacol Ther 14:1451–1457, 2000PubMedGoogle Scholar
  103. 103.
    Lanza FL, Rack MF, Li Z, Krajewski SA, Blank MA: Placebocontrolled, randomized, evaluator-blinded endoscopy study of risedronate vs. aspirin in healthy postmenopausal women. Aliment Pharmacol Ther 14:1663–1670, 2000PubMedGoogle Scholar
  104. 104.
    Rimmer DE, Rawls DE: Improper alendronate administration and a case of pill esophagitis. Am J Gastroenterol 91:2648–2649, 1996PubMedGoogle Scholar
  105. 105.
    Girelli CM, Reguzzoni G, Rocca F: Alendronate-induced esophagitis. A report of two cases. Recenti Prog Med 88:223–225, 1997PubMedGoogle Scholar
  106. 106.
    Devogelaer JP, Broll H, Correa-Rotter R, Cumming DC, De Deuxchaisnes CN, Geusens P, Hosking D, Jaeger P, Kaufman JM, Leite M, Leon J, Liberman U, Menkes CJ, Meunier PJ, Reid I, Rodriguez J, Romanowicz A, Seeman E, Vermeulen A, Hirsch LJ, Lombardi A, Plezia K, Santora AC, Yates AJ, Yuan W: Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 18:141–150, 1996PubMedGoogle Scholar
  107. 107.
    Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ, Stych B: Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study. Foxamax International Trial Study Group. Osteoporos Int 9:461–468, 1999PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 2002

Authors and Affiliations

  • David Y. Graham
    • 1
    • 2
  1. 1.Department of MedicineVA Medical CenterHoustonUSA
  2. 2.Baylor College of MedicineHoustonUSA

Personalised recommendations